Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2001 5
2002 5
2003 2
2004 4
2005 2
2006 1
2007 2
2008 4
2009 6
2010 9
2011 3
2012 9
2013 4
2014 10
2015 9
2016 11
2017 11
2018 12
2019 18
2020 16
2021 23
2022 21
2023 14
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

180 results

Results by year

Filters applied: . Clear all
Page 1
Emerging molecular subtypes and therapies in acute lymphoblastic leukemia.
Davis K, Sheikh T, Aggarwal N. Davis K, et al. Semin Diagn Pathol. 2023 May;40(3):202-215. doi: 10.1053/j.semdp.2023.04.003. Epub 2023 Apr 9. Semin Diagn Pathol. 2023. PMID: 37120350 Review.
The established B-ALL entities include B-ALL with BCR::ABL1 fusion, BCR::ABL1-like features, KMT2A rearrangement, ETV6::RUNX1 rearrangement, high hyperdiploidy, hypodiploidy (focusing on near haploid and low hypodiploid), IGH::IL3 rearrangement, TCF3::PBX1 rearrange …
The established B-ALL entities include B-ALL with BCR::ABL1 fusion, BCR::ABL1-like features, KMT2A rearrangement, ETV6::RUNX1 rearran …
Molecular classification improves risk assessment in adult BCR-ABL1-negative B-ALL.
Paietta E, Roberts KG, Wang V, Gu Z, Buck GAN, Pei D, Cheng C, Levine RL, Abdel-Wahab O, Cheng Z, Wu G, Qu C, Shi L, Pounds S, Willman CL, Harvey R, Racevskis J, Barinka J, Zhang Y, Dewald GW, Ketterling RP, Alejos D, Lazarus HM, Luger SM, Foroni L, Patel B, Fielding AK, Melnick A, Marks DI, Moorman AV, Wiernik PH, Rowe JM, Tallman MS, Goldstone AH, Mullighan CG, Litzow MR. Paietta E, et al. Blood. 2021 Sep 16;138(11):948-958. doi: 10.1182/blood.2020010144. Blood. 2021. PMID: 33895809 Free PMC article. Clinical Trial.
Transcriptome sequencing, gene expression profiling, cytogenetics, and fusion polymerase chain reaction enabled genomic subtyping of 282 patient samples, of which 264 were eligible for trial, accounting for 64.5% of E2993 patients. Among patients with outcome data, 29.5% w …
Transcriptome sequencing, gene expression profiling, cytogenetics, and fusion polymerase chain reaction enabled genomic subtyping of …
Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies.
Padella A, Ghelli Luserna Di Rorà A, Marconi G, Ghetti M, Martinelli G, Simonetti G. Padella A, et al. J Hematol Oncol. 2022 Jan 22;15(1):10. doi: 10.1186/s13045-022-01228-0. J Hematol Oncol. 2022. PMID: 35065680 Free PMC article. Review.
Despite the low frequency of genomic alterations of PARP and other DDR-related genes in acute leukemia, selective vulnerabilities have been reported in several disease subgroups, along with a "BRCAness phenotype." AML carrying the RUNX1-RUNX1T1 or PML-RARA fusion genes or …
Despite the low frequency of genomic alterations of PARP and other DDR-related genes in acute leukemia, selective vulnerabilities have been …
NGS-based methylation profiling differentiates TCF3-HLF and TCF3-PBX1 positive B-cell acute lymphoblastic leukemia.
Kachroo P, Szymczak S, Heinsen FA, Forster M, Bethune J, Hemmrich-Stanisak G, Baker L, Schrappe M, Stanulla M, Franke A. Kachroo P, et al. Epigenomics. 2018 Feb;10(2):133-147. doi: 10.2217/epi-2017-0080. Epub 2018 Jan 15. Epigenomics. 2018. PMID: 29334255
AIM: To determine whether methylation differences between mostly fatal TCF3-HLF and curable TCF3-PBX1 pediatric acute lymphoblastic leukemia subtypes can be associated with differential gene expression and remission. MATERIALS & METHODS: Five (extremely rare) …
AIM: To determine whether methylation differences between mostly fatal TCF3-HLF and curable TCF3-PBX1 pediatric acute lymphobl …
Transcriptional landscape of B cell precursor acute lymphoblastic leukemia based on an international study of 1,223 cases.
Li JF, Dai YT, Lilljebjörn H, Shen SH, Cui BW, Bai L, Liu YF, Qian MX, Kubota Y, Kiyoi H, Matsumura I, Miyazaki Y, Olsson L, Tan AM, Ariffin H, Chen J, Takita J, Yasuda T, Mano H, Johansson B, Yang JJ, Yeoh AE, Hayakawa F, Chen Z, Pui CH, Fioretos T, Chen SJ, Huang JY. Li JF, et al. Proc Natl Acad Sci U S A. 2018 Dec 11;115(50):E11711-E11720. doi: 10.1073/pnas.1814397115. Epub 2018 Nov 28. Proc Natl Acad Sci U S A. 2018. PMID: 30487223 Free PMC article.
Apart from extending eight previously described subgroups (G1 to G8 associated with MEF2D fusions, TCF3-PBX1 fusions, ETV6-RUNX1-positive/ETV6-RUNX1-like, DUX4 fusions, ZNF384 fusions, BCR-ABL1/Ph-like, high hyperdiploidy, and KMT2A fusions …
Apart from extending eight previously described subgroups (G1 to G8 associated with MEF2D fusions, TCF3-PBX1 fusions, E …
Transcription factor abnormalities in B-ALL leukemogenesis and treatment.
Yin H, Wang J, Tan Y, Jiang M, Zhang H, Meng G. Yin H, et al. Trends Cancer. 2023 Oct;9(10):855-870. doi: 10.1016/j.trecan.2023.06.004. Epub 2023 Jul 3. Trends Cancer. 2023. PMID: 37407363 Review.
We provide an in-depth review of molecular mechanisms of six major TF rearrangements in B-ALL, including DUX4-rearranged (DUX4-R), MEF2D-R, ZNF384-R, ETV6-RUNX1 and TCF3-PBX1 fusions, and KMT2A-R. In addition, the therapeutic options and prognoses for patients who h …
We provide an in-depth review of molecular mechanisms of six major TF rearrangements in B-ALL, including DUX4-rearranged (DUX4-R), MEF2D-R, …
Whole-transcriptome analysis in acute lymphoblastic leukemia: a report from the DFCI ALL Consortium Protocol 16-001.
Tran TH, Langlois S, Meloche C, Caron M, Saint-Onge P, Rouette A, Bataille AR, Jimenez-Cortes C, Sontag T, Bittencourt H, Laverdière C, Lavallée VP, Leclerc JM, Cole PD, Gennarini LM, Kahn JM, Kelly KM, Michon B, Santiago R, Stevenson KE, Welch JJG, Schroeder KM, Koch V, Cellot S, Silverman LB, Sinnett D. Tran TH, et al. Blood Adv. 2022 Feb 22;6(4):1329-1341. doi: 10.1182/bloodadvances.2021005634. Blood Adv. 2022. PMID: 34933343 Free PMC article. Clinical Trial.
RNA-seq identified at least 1 alteration in 157 patients (91%). Fusion detection was 100% concordant with results obtained from conventional cytogenetic analyses. An additional 56 gene fusions were identified by RNA-seq, many of which confer prognostic or therapeuti …
RNA-seq identified at least 1 alteration in 157 patients (91%). Fusion detection was 100% concordant with results obtained from conve …
Characterization of TCF3 rearrangements in pediatric B-lymphoblastic leukemia/lymphoma by mate-pair sequencing (MPseq) identifies complex genomic rearrangements and a novel TCF3/TEF gene fusion.
Rowsey RA, Smoley SA, Williamson CM, Vasmatzis G, Smadbeck JB, Ning Y, Greipp PT, Hoppman NL, Baughn LB, Ketterling RP, Peterson JF. Rowsey RA, et al. Blood Cancer J. 2019 Oct 1;9(10):81. doi: 10.1038/s41408-019-0239-z. Blood Cancer J. 2019. PMID: 31575852 Free PMC article.
While dual-color, dual-fusion fluorescence in situ hybridization (D-FISH) probes can detect TCF3/PBX1 fusions, further characterization of atypical TCF3 FISH patterns as indicated by additional or diminished TCF3 signals is currently limited. .. …
While dual-color, dual-fusion fluorescence in situ hybridization (D-FISH) probes can detect TCF3/PBX1 fusions, further …
Classification and genetics of pediatric B-other acute lymphoblastic leukemia by targeted RNA sequencing.
Migita NA, Jotta PY, Nascimento NPD, Vasconcelos VS, Centoducatte GL, Massirer KB, Azevedo AC, Brandalise SR, Yunes JA. Migita NA, et al. Blood Adv. 2023 Jul 11;7(13):2957-2971. doi: 10.1182/bloodadvances.2022009179. Blood Adv. 2023. PMID: 36848637 Free PMC article.
Here, targeted RNA sequencing was used to identify the novel subgroups of ALL in 144 B-other and 40 "classical" ALL samples. The classical TCF3-PBX1, ETV6-RUNX1, KMT2A-rearranged, and BCR-ABL1, and novel P2RY8-CRLF2, ABL-, JAK2-, ZNF384-, MEF2D-, and NUTM1-fusions w …
Here, targeted RNA sequencing was used to identify the novel subgroups of ALL in 144 B-other and 40 "classical" ALL samples. The classical …
Clinical features and prognostic significance of TCF3-PBX1 fusion gene in Chinese children with acute lymphoblastic leukemia by using a modified ALL-BFM-95 protocol.
Pang L, Liang Y, Pan J, Wang JR, Chai YH, Zhao WL. Pang L, et al. Pediatr Hematol Oncol. 2015 Apr;32(3):173-81. doi: 10.3109/08880018.2014.983625. Epub 2014 Dec 31. Pediatr Hematol Oncol. 2015. PMID: 25551271
For children with precursor B (pre-B) acute lymphoblastic leukemia (ALL) with TCF3-PBX1 fusion gene, their prognosis has been a controversial topic. ...Eighty five cases without TCF3-PBX1 in the same IR group were regarded as the comparison group. ...
For children with precursor B (pre-B) acute lymphoblastic leukemia (ALL) with TCF3-PBX1 fusion gene, their prognosis has been …
180 results